Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neumedicines Inc.

Latest From Neumedicines Inc.

US BARDA awards $56.3 million to advance radiation injury treatments

Araim Pharmaceuticals, Cellerant Therapeutics, Neumedicines, RxBio and the University of Arkansas were awarded a total of $56.3 million by the US Biomedical Advanced Research and Development Authority (BARDA) to develop new therapies to treat bone marrow, gastrointestinal, lung and skin injuries associated with acute radiation syndrome (ARS) caused by exposure to high doses of radiation, such as after denotation of an improvised nuclear device.

Cardiovascular Metabolic Disorders

Neumedicines Inc.

Neumedicines Inc. is developing IL-12-based therapeutics to restore hematopoiesis. Its lead compound HemaMax, recombinant human IL-12, is designed to regenerate the hematopoeietic system following exposure to radiation. A second program, HemaMax-II, will likely focus initially on treating chemotherapy-induced leucopenia, neutropenia, anemia and thrombocytopenia.

Start-Up Previews (12/2009)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bringing New Blood to the Anemia Market," features profiles of Akebia, Neumedicines and Palkion. Plus these Start-Ups Across Health Care: Aterovax, Pico-Tesla Magnetic Therapies, SpineAlign Medical, Theraclion, Virdante Pharmaceuticals and Zacharon Pharmaceuticals.
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neumedicines Inc.
  • Senior Management
  • Lena A Basile, PhD, Chmn. & CEO
    David L Morash, Pres. & Chief Strategy Officer
  • Contact Info
  • Neumedicines Inc.
    Phone: (626) 844-3800
    133 North Altadena Dr.
    Ste. 310
    Pasadena, CA 91107